摘要
目的 提示临床奥马珠单抗注射剂联合治疗中重度过敏性哮喘使用过程中需加以关注可能引起的迟发型皮肤过敏反应。方法 分析1例奥马珠单抗注射剂联合治疗中重度过敏性哮喘过程中,发生迟发型过敏大面积皮疹,通过不良反应相关性分析鉴别该患者发生不良反应的可能药物和处理措施。结果 患者不良反应为迟发型大面积过敏皮疹,排除患者病情和合并用药情况,判断引起患者严重大面积皮疹的原因为注射使用奥马珠单抗。不良反应相关性评价为“肯定”,立即予以停药并对症处理后患者好转,未发生后遗症。结论 临床应加强监测奥马珠单抗注射剂引起的迟发型不良反应并及时采取措施,以免造成严重后果。
Objective To warn against potential delayed large-area allergic skin rashes as an adverse reaction during the combined treatment of severe allergic asthma using omalizumab injection.Methods One case of delayed onset allergic large-area rash occurred during the treatment of moderate to severe allergic asthma with omalizumab injection.The possible drugs responsible for the adverse reaction and countermeasures were identified based on adverse reaction correlation analysis.Results The adverse reaction in this patient manifested as a delayed large-area allergic skin rash.After such factors as the patient’s condition and concurrent medication were ruled out,the injection of omalizumab was considered to be the cause of the severe skin rash.The adverse reaction correlation was evaluated as“definite”.Immediate discontinuation of the medication and appropriate symptomatic treatment led to the patient’s recovery without any residual effects.Conclusion In clinical practice,delayed adverse reactions caused by omalizumab injection have to be monitored and immediate measures taken to prevent serious consequences.
作者
李娜
郭军
郭文佳
吕茵茵
李彩宏
牟向东
LI Na;GUO Jun;GUO Wenjia;LYU Yinyin;LI Caihong;MU Xiangdong(Department of Respiratory and Critical Care Medicine,Beijing Tsinghua Changgung Hospital,School of Clinical Medicine,Tsinghua University,Beijing 102218,China)
出处
《中国药物警戒》
2024年第2期211-212,222,共3页
Chinese Journal of Pharmacovigilance
基金
2022年度北京市重大疫情防治重点专科项目
北京清华长庚医院研究基金(22021C1002)。
